Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Drimane-type sesquiterpenoids from aspergillus keveioides under OSMAC strategy characterized by GNPS possess in vitro antitumor cytotoxicity: A combined approach of bioactivity assay and network pharmacology.

Created on 13 Sep 2026

Authors

Tiantian Qu, Changcheng Zhu, Lingyu Fang, Jiahao Gu, Ying Wang, Xiaoxu Bi, Jie Luan, Jian Tao, Jiangbo He

Published in

Fitoterapia. Pages 107462. Sep 12, 2026. Epub Sep 12, 2026.

Abstract

Guided by LC-MS/MS and Global Natural Products Social Molecular Networking (GNPS), two new drimane-type sesquiterpenoids, ustusolates H and I, along with eleven known analogues, were isolated from the fermentation broth of Aspergillus keveioides. Their chemical structures were elucidated on the basis of comprehensive spectroscopic data. All isolated compounds were assessed for cytotoxicity against four human cancer cell lines, including HeLa, BGC-823, HCT-116 and MIAPaCa-2. Compound 7 exerted potent inhibitory activity toward BGC-823 and MIAPaCa-2 cells, while compound 11 showed remarkable cytotoxic effects against BGC-823 and HCT-116 cells. Further combined with network pharmacology, we screened potential drug targets and explored the binding modes via molecular docking. This study not only expands the chemical diversity of fungal drimane-type sesquiterpenoids, but also provides a theoretical basis for further research and exploitation of this class of metabolites.

PMID:
42731708
Bibliographic data and abstract were imported from PubMed on 13 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement